tbuckley/cabot-search huggingface dataset:
Detection of the MYD88 L265P mutation in Waldenström’s macroglobulinemia using a highly sensitive allele-specific PCR assay.
Authors: Lian Xu, Zachary R Hunter, Guang Yang, Yang Cao, Xia Liu, Yangsheng Zhou, Christopher J Patterson, Robert J Manning, Christina Tripsas, Patricia S Sheehy, Neal Ian Lindeman, Steven P. Treon
Journal: Journal of Clinical Oncology (2012)

8042 Background: Waldenström’s macroglobulinemia (WM) is a B-cell malignancy characterized by bone marrow (BM) infiltration with lymphoplasmacytic cells and production of an IgM paraprotein. By whole genome sequencing, we recently identified a somatic mutation (L265P) in the MYD88 gene in 27/30 (90%) WM patients (Treon et al, ASH 2011). To expand this finding for possible diagnostic testing, we developed an allele-specific PCR assay for MYD88 L265P and evaluated this assay in a large cohort of WM patients. Methods: An allele-specific PCR assay was developed with a threshold of detection of 0.125% for MYD88 L265P. DNA from bone marrow aspirates from 99 patients with the clinicopathological diagnosis of WM was used for assessment of MYD88 L265P expression by both allele-specific PCR and Sanger sequencing. Findings were correlated with clinical parameters using ANOVA. Results: We observed that 85/99 (86%) WM patients were positive for MYD88 L265P using the allele-specific PCR assay. Of the 85 allele-specific PCR positive patients, 81 demonstrated a detectable mutation peak by Sanger sequencing. All 14 allele-specific PCR negative patients remained negative by Sanger sequencing. By the allele-specific PCR assay, MYD88 L265P positive patients showed greater bone marrow involvement, higher serum IgM and lower serum IgA and IgG levels versus MYD88 L265P negative patients (p&lt;0.008). Conclusions: MYD88 L265P is highly expressed in BM samples of WM patients using an allele-specific PCR assay, and is associated with greater bone marrow disease burden and serum IgM levels. Use of allele-specific PCR provides a simple and sensitive diagnostic tool for detection of the MYD88 L265P mutation.
IMPACT OF BASELINE CHRONIC KIDNEY DISEASE ON OUTCOMES OF TRANSCATHETER MITRAL VALVE REPAIR (MITRACLIP)
Authors: Hitesh Raheja, Keerat Rai Ahuja, Salik Nazir, Anas Saad, Mohamed M. Gad, Kirti Chopra, Sunny Goel, Bilal Malik, Jacob Shani, Robert Frankel, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
ELECTRICAL STORM AND CARDIOGENIC SHOCK AFTER ACUTE CORONARY SYNDROME REVERTED WITH ECMO CASE REPORT
Authors: Mayara Reis Cardoso Ferreira, Luciano Moreira Baracioli, Filomena Regina Barbosa Gomes Galas, Talia Dalcoquio, Remo Holanda Furtado, Vanessa Maria Gomes Taques Baldo, Carla David Soffiatti, Adriadne Justi Bertolin, Sumaia Mustafa, Daniely Iadocico Sobreiro, Jose Carlos Nicolau
Journal: Journal of the American College of Cardiology (2020)
ISOLATED SYSTOLIC HYPERTENSION VERSUS COMBINED SYSTOLIC-DIASTOLIC HYPERTENSION AS PREDICTOR OF ATRIAL FIBRILATION: DATA FROM AN 8-YEAR-FOLLOW-UP STUDY
Authors: Konstantinos P. Tsioufis, Dimitris Konstantinidis, Kyriakos Dimitriadis, Alexandros Kasiakogias, Ioannis Liatakis, Evaggelia Koutra, Ioannis Leontsinis, Mairh Kouremeti, Panayiotis Iliakis, Nikos Karaminas, Margarita Dimitriadi, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2020)
NATIONAL TRENDS OF TOBACCO, ALCOHOL, AND DRUG ABUSE IN PATIENTS ADMITTED WITH ACUTE MYOCARDIAL INFARCTION
Authors: Amer N. Kadri, Asadullah Mahmood, Leen Nusairat, Sara Khodor, Ahmed Ali, Ammar ELJack, Cristian Chagas, Najeebullah Bangash, Mohamed M. Gad, Johnny Chahine, Syed Jafri, Steven W. Werns
Journal: Journal of the American College of Cardiology (2020)
Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients
Authors: Maria L. Espinosa, Morgan T. Nguyen, Amaia Saenz Aguirre, Maria Estela Martinez-Escala, Jane Kim, Christina J. Walker, David S. Pontes, Jonathan I. Silverberg, Jaehyuk Choi, Barbara Pro, Laura B. Pincus, Joan Guitart, Xiaolong A. Zhou
Journal: Journal of the American Academy of Dermatology (2020)
TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION CANNOT PREDICT THE OUTCOME OF HEART FAILURE WITH PRESERVED EJECTION FRACTION AND SINUS RHYTHM
Authors: Masayuki Nakamura, Haruhiko Abe, Yoshinori Iida, Chieko Toriyama, Takuya Ohashi, Kotaro Takayasu, Tatsuhisa Ozaki, Shumpei Kosugi, Kazuya Shinouchi, Tsuyoshi Mishima, Motoo Date, Yasunori Ueda, Masaaki Uematsu, Yukihiro Koretsune
Journal: Journal of the American College of Cardiology (2020)
Ventilation defects on hyperpolarized helium-3 MRI in asthma are predictive of 2-year exacerbation frequency
Authors: David G. Mummy, Katherine J. Carey, Michael D. Evans, Loren C. Denlinger, Mark L. Schiebler, Ronald L. Sorkness, Nizar N. Jarjour, Sean B. Fain
Journal: Journal of Allergy and Clinical Immunology (2020)
CHRONIC DEFIBRILLATION THRESHOLD TESTING IN PATIENTS UNDERGOING SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR GENERATOR CHANGE
Authors: Raj Patel, Ahmed Shahab, Michael Broman, Zaid Aziz, Andrew D. Beaser, Gaurav A. Upadhyay, Arun Kannan, Zenith Jameria, Andrew Chen, Cevher Ozcan, Roderick Tung, Hemal M. Nayak
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF TRANSCATHETER TRICUSPID VALVE REPAIR ON DAILY PHYSICAL ACTIVITY: AN ANALYSIS OF WEARABLE ACTIVITY MONITORING IN THE CLASP TR EARLY FEASIBILITY STUDY
Authors: Philip Green, Christine Chung, Shannon Murphy, Ahmad Al-Ghusain, Sarah Mollenkopf, Ted Feldman, Charles Davidson, Mackram Eleid, Robert Kipperman, Robert Smith, Scott Lim, Firas Zahr, William A. Gray, Adam Greenbaum, Martin Leon, Susheel K. Kodali
Journal: Journal of the American College of Cardiology (2020)
Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results.
Authors: Mary E. Cianfrocca, Virginia G. Kaklamani, Steven T. Rosen, Jamie H. Von Roenn, Alfred Rademaker, Deborah A. Smith, Stephen D. Rubin, Caitlin Meservey, Regina Uthe, William John Gradishar
Journal: Journal of Clinical Oncology (2012)

610 Background: Liposomal formulations including pegylated liposomal doxorubicin (PLD) were developed to improve the therapeutic index of anthracyclines (A). Lapatinib (L) is a selective, highly competitive inhibitor of ErbB1 and ErbB2 tyrosine kinases. Conventional doxorubicin plus trastuzumab was effective but with unacceptable cardiac toxicity. PLD plus L may be effective with less cardiac risk. Methods: This is a phase I, dose-escalation trial of PLD 20, 30, 45 and 60 mg/m 2 IV every 4 weeks (maximum of 8 doses) and L, 1500 mg po daily until progression in patients (pts) with MBC. ErbB2 positivity was not required. Prior chemotherapy, endocrine therapy and trastuzumab were allowed. A subsequent amendment allowed prior L. Prior A use was limited to 240 mg/m 2 of doxorubicin or 600 mg/m 2 of epirubicin. Concomitant CYP3A4 inducers/ inhibitors were not allowed. A left ventricular ejection fraction (LVEF) of &gt; 50% was required. The primary objective was to evaluate the safety (particularly cardiac), tolerability and feasibility of PLD and L. Results: 23 pts (PLD: 20 mg/m 2 - 4 pts; 30 mg/m 2 - 3 pts; 45 mg/m 2 – 13 pts; 60 mg/m 2 - 3 pts) have been treated; total of 73 treatment cycles. Dose-limiting toxicity (DLT) was not reached. One pt had an LVEF drop to &lt; 50% after 4 cycles accompanied by a pericardial effusion due to progressive disease. Treatment-related grade III/IV adverse events included: 4 pts with hand-foot-syndrome (HFS), 2 pts each with leukopenia, infection, and skin changes, 1 pt each with pain, fatigue, diarrhea, mucositis, hypoalbuminemia, anemia, cough, pleural effusion, and edema. Grade 3 HFS occurred in 2 of 3 pts in the 60 mg/m 2 cohort. Response data in 21 evaluable pts: 4 PR, 5 SD, and 12 PD. Preliminary pharmacokinetic (PK) analyses (7 pts) indicate L has no effect on PLD (45 mg/m 2 ) concentrations, but L concentrations were approximately 2-fold higher the day of PLD dosing. Conclusions: In 23 pts treated, PLD plus L was well tolerated with manageable toxicities and no treatment-related cardiac toxicity. DLT was not reached however grade 3 HFS occurred in 2 of 3 pts in the 60 mg/m 2 cohort. Preliminary PK analyses demonstrate no effect of L on PLD, but an effect of PLD on L the day of PLD dosing.
NOVEL DIAGNOSTIC APPROACH TO THE DETECTION AND THE TREATMENT OF VULNERABLE CORONARY PLAQUES USING COLOR MAPPED CORONARY CT ANGIOGRAPHY AND ANTI-PCSK9 ANTIBODY
Authors: Aizan Hirai, Seiya Kondo, Toshio Goto, Keiji Hirai, Norihumi Kamiya, Isao Komesu, Yuki Tanabe, Kazutoshi Okuzaki, Keisuke Yamada, Takahumi Arai, Hidekazu Moromizato, Hiroshi Sunagawa, Teruhito Kido
Journal: Journal of the American College of Cardiology (2020)
Association of Declines in End-of-Life Health Care Costs With Fee-for-Service Enrollee Per Capita Expenditures
Authors: William B. Weeks, Stacey Y. Cao, Chris M. Lester, James N. Weinstein
Journal: JAMA Network Open (2020)

This cross-sectional study assesses the association between end-of-life health care costs and fee-for-service Medicare spending and examines whether expenditures attributed to decedents have changed over time.
PREVALENCE AND TESTING OF LIPOPROTEIN(A) AMONG YOUNG ADULTS WITH MYOCARDIAL INFARCTION: THE PARTNERS YOUNG-MI REGISTRY
Authors: Adam Berman, David Biery, Avinainder Singh, Wanda Wu, Sanjay Divakaran, Ersilia DeFilippis, Josh Klein, Jon Hainer, Michael Blaha, Christopher P. Cannon, Donna M. Polk, Jorge Plutzky, Pradeep Natarajan, Khurram Nasir, Marcelo Di Carli, Deepak Bhatt, Ron Blankstein
Journal: Journal of the American College of Cardiology (2020)
IMPLANTATION FEASIBILITY AND EARLY VASCULAR RESPONSE OF A NOVEL PLLA/PLGA BIORESORBABLE SCAFFOLD IN PORCINE CORONARY IN-STENT RESTENOSIS MODEL
Authors: Piotr P. Buszman, Mateusz Kachel, Magdalena Michalak, Marta Konopko, Michał Sobota, Jerzy Małachowski, Pawel Buszman, Krzysztof Milewski
Journal: Journal of the American College of Cardiology (2020)
CARDIOMYOCYTE-SPECIFIC DELETION OF PLASMA MEMBRANE CALCIUM ATPASE1 (PMCA1CKO) EXACERBATES CARDIAC REMODELLING AFTER TRANSVERSE AORTIC CONSTRICTION LEADING TO DILATED CARDIOMYOPATHY IN MURINE MODEL
Authors: Tahir Nazir, Florence Baudoin, Min Zi, Sukhpal Prehar, Elizabeth J. Cartwright
Journal: Journal of the American College of Cardiology (2020)
THE ALIGNMENT OF TRANSCATHETER AORTIC VALVE NEO-COMMISSURES (ALIGN TAVR) STUDY
Authors: Gilbert Hin-Lung Tang, Syed Zaid, Andreas Fuchs, Tsuyoshi Yamabe, Farhang Yazdchi, Eisha Gupta, Hasan Ahmad, Klaus Kofoed, Joshua Goldberg, Cenap Undemir, Ryan Kaple, Pinak Shah, Steven Lansman, George D. Dangas, Stamatios Lerakis, Samin K. Sharma, Annapoorna Subhash Kini, Omar K. Khalique, Rebecca T. Hahn, Lars Sondergaard, Isaac George, Susheel K. Kodali, Ole De Backer, Martin Leon, Vinayak Bapat
Journal: Journal of the American College of Cardiology (2020)
OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity
Authors: Kate Poropatich, Donye Dominguez, Wen-Ching Chan, Jorge Andrade, Yuanyuan Zha, Brian Wray, Jason Miska, Lei Qin, Lisa Cole, Sydney Coates, Urjeet Patel, Sandeep Samant, Bin Zhang
Journal: Journal of Clinical Investigation (2020)

Plasmacytoid DCs (pDCs), the major producers of type I interferon, are principally recognized as key mediators of antiviral immunity. However, their role in tumor immunity is less clear. Depending on the context, pDCs can promote or suppress antitumor immune responses. In this study, we identified a naturally occurring pDC subset expressing high levels of OX40 (OX40+ pDC) enriched in the tumor microenvironment (TME) of head and neck squamous cell carcinoma. OX40+ pDCs were distinguished by a distinct immunostimulatory phenotype, cytolytic function, and ability to synergize with conventional DCs (cDCs) in generating potent tumor antigen-specific CD8+ T cell responses. Transcriptomically, we found that they selectively utilized EIF2 signaling and oxidative phosphorylation pathways. Moreover, depletion of pDCs in the murine OX40+ pDC-rich tumor model accelerated tumor growth. Collectively, we present evidence of a pDC subset in the TME that favors antitumor immunity.
Annals Graphic Medicine - Make a Wish
Authors: Lucia Briatore, Ilaria Pozzi
Journal: Annals of Internal Medicine (2020)

Web Exclusives17 March 2020Annals Graphic Medicine - Make a WishFREELucia Briatore, MD, PhD and Ilaria PozziLucia Briatore, MD, PhDSavona, Italy (L.B., I.P.)Search for more papers by this author and Ilaria PozziSavona, Italy (L.B., I.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0021 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Savona, Italy (L.B., I.P.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G19-0021.Author/Illustrator Information: Lucia Briatore, MD, PhD, is an internist and diabetologist working in Pietra Ligure, Savona, Italy. Ilaria Pozzi is a freelance illustrator in Savona, Italy.Written by Lucia Briatore, MD, PhD, and illustrated by Ilaria Pozzi. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 March 2020Volume 172, Issue 6Page: W82-W84KeywordsDisclosureHealth care ePublished: 17 March 2020 Issue Published: 17 March 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Cognitive load theory and differential attainment
Authors: William Atiomo
Journal: BMJ (2020)

Linton discusses a multi-pronged approach to tackling differential attainment.1 Another approach, not considered by Linton or the General Medical Council in its report published last year,2 is using the framework of cognitive load theory.

Cognitive load theory proposes that, when learning, new information is stored in working memory, which is limited in …
CARDIOMYOPATHY IN PREGNANCY - RISK IN THE ERA OF GOAL-DIRECTED MEDICAL THERAPY: A TERTIARY CARE CENTER EXPERIENCE &amp; SYSTEMATIC REVIEW
Authors: Anudeep Dodeja, Francesca Urbina, Katherine Dodd, Marwan Ma'ayeh, Laxmi Mehta, Margaret Fuchs, Kara Rood, May Ling Mah, Elisa Bradley
Journal: Journal of the American College of Cardiology (2020)
Childhood nasopharyngeal carcinoma: A 4-year single institution experience
Authors: A. A. Patel, P. M. Shah, K. M. Patel, S. N. Shukla, B. J. Parikh, A. S. Anand, S. A. Shah, S. S. Talati, H. P. Panchal, R. Pandey
Journal: Journal of Clinical Oncology (2006)

9069 Background: Pediatric nasopharyngeal carcinoma (PNC) represents a locally advanced undifferentiated tumor. In this study, clinical experience and therapeutic results of 24 children with newly diagnosed PNC, treated in a single oncology institution in India over a period of 5 years, are analyzed. Methods: 24 patients (23 males and 1 female) 7–14 years old (median = 12) from Jan 2000 to Sep 2005 with PNC were retrospectively evaluated. 18/24 patients were evaluable. 16 patients received induction chemotherapy followed by radiotherapy while 1 patient was offered concurrent chemoradiotherapy, 1 patient received radiotherapy alone. 15/16 patients received postradiation chemotherapy. The agents used in induction and adjuvant therapy were cisplatin (100 mg/m 2 ) on day 1 and 5-fluorouracil 750 mg/m 2 for 5 days. The dose of radiotherapy used was 60 gray in 30 fractions. Results: The time of onset of symptoms to diagnosis ranged from 1 month to 9 months with a median of 5.5 months. Histopathology was lymphoepithelioma in 5 patients (27.7%) while 13 patients (72.2%) had poorly differentiated carcinoma. Disease extent was T2 (n = 7), T3 (n = 6), and T4 (n = 5); N1 (n = 5), N2 (n = 7), and N3 (n = 5). 7 patients had intracranial invasion. None had metastatic disease on presentation. 13 patients (72.2%) achieved major response which included 7 (38.8%) complete remission and 6 (33.3%) partial remission after the induction chemotherapy and radiotherapy. 4 (22.2%) had progressive disease. Another 3 (16.6%) attained complete remission after post radiation chemotherapy which consisted of two cycles of cisplatin and 5-flourouracil. The follow up ranged from 5 months to 84 months with a median follow up of 35 months. The disease free survival ranged from 10 months to 53 months with a median of 33 months. The patients who had a better response to induction chemotherapy had a better disease free survival. Out of 7 patients who attained complete remission 2 relapsed with a median time to first relapse of 9.5 months. Toxicity to therapy was modest. Only one patient had grade 4 neutropenia and mucositis. There was no therapy related mortality. Conclusion: Chemoradiotherapy for nasopharyngeal carcinoma in children is an effective treatment modality with minimal toxicity. No significant financial relationships to disclose.
ROLE OF CARDIAC SYMPATHETIC DENERVATION IN VENTRICULAR TACHYCARDIA: A META-ANALYSIS
Authors: Ghulam Murtaza, Sharan Sharma, Krishna Akella, Domenico Della Rocca, Donita Atkins, Dhanunjaya R. Lakkireddy, Rakesh Gopinathannair
Journal: Journal of the American College of Cardiology (2020)
Cost-effectiveness of niraparib versus routine surveillance, olaparib, and rucaparib for the maintenance treatment of adult patients with ovarian cancer in the United States.
Authors: Mark Fisher, Holly Guy, Lydia Walder
Journal: Journal of Clinical Oncology (2018)

5559 Background: To estimate the cost-effectiveness of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, compared with routine surveillance (RS), olaparib and rucaparib for the maintenance treatment of patients with recurrent ovarian cancer. Methods: A decision-analytic model estimated the cost per quality-adjusted life-year gained for niraparib versus RS, olaparib and rucaparib from a US payer perspective. Recurrent ovarian cancer patients with or without germline BRCA mutation, who were responsive to their last platinum-based chemotherapy regimen, entered the model (non-gBRCAmut, gBRCAmut). The model had three health states; progression-free disease, progressed disease and dead. For non-gBRCAmut and gBRCAmut, mean progression-free survival (PFS) was estimated for niraparib and RS, and rucaparib using parametric survival distributions based on ENGOT-OV16/NOVA (Niraparib Phase III trial) and ARIEL3 (Rucaparib Phase III trial), respectively. For non-gBRCAmut, olaparib PFS was estimated from Study 19 (Olaparib Phase II trial). For gBRCAmut, a cost-minimisation analysis was conducted versus olaparib. Due to immature overall survival (OS) data in ENGOT-OV16/NOVA and ARIEL3, mean OS benefit was estimated as double the mean PFS benefit for niraparib, olaparib and rucaparib versus RS. Costs included; drug, chemotherapy, monitoring, adverse events, and terminal care. EQ-5D captured quality-of-life. A 3% annual discount rate was used. Results: Treatment with niraparib increased costs and QALYs versus RS, with an incremental cost-effectiveness ratio of $94,186 and $58,804, for non-gBRCAmut and gBRCAmut. Niraparib had lower costs and higher QALYs compared to olaparib and rucaparib in both populations, with a cost difference of -$57,575 and -$60,400 versus olaparib, and a cost difference of -$117,916 and -$261,950 versus rucaparib for non-gBRCAmut and gBRCAmut. Conclusions: These estimates indicate that niraparib was cost-effective compared to olaparib and rucaparib. Additionally, the cost-effectiveness ratio falls within an acceptable range versus RS. Mature OS data is required to validate these results.
No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
Authors: Lilian Iglesias, Sudipto Mukherjee, Aziz Nazha, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Jaroslaw P. Maciejewski, Navneet S. Majhail, Mikkael A. Sekeres
Journal: Blood (2017)
Estrogen receptor (ER), Ki-67, p27<sup>Kip1</sup>, and histologic grade as predictors of pathologic complete response (pCR) in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy (NAC) using fluorouracil, epirubicin, and cyclophosphamide (FEC), taxanes, and trastuzumab.
Authors: Sasagu Kurozumi, Kenichi Inoue, Hiroyuki Takei, Hiroshi Matsumoto, Takashi Yoshida, Yuji Hayashi, Jun Ninomiya, Kazuyuki Kubo, Shigenori E Nagai, Hanako Oba, Masafumi Kurosumi, Toshio Tabei, Jun Horiguchi, Izumi Takeyoshi
Journal: Journal of Clinical Oncology (2012)

613 Background: NAC with taxanes and FEC concurrently with trastuzumab is a potent regimen in patients with HER2-positive breast cancer (BC). Several studies revealed high pCR rates in BC patients treated with this regimen; however, predictive factors and a prognostic effect of pCR have been still unclear. In this study, we analyzed several factors including p27 Kip1 (cyclin-dependent kinase inhibitor acting as tumor suppressor) for correlation with pCR. We also evaluated differences in recurrence-free survival (RFS) or overall survival (OS) between patients with pCR and non-pCR, and with positive and negative nodes after NAC. Methods: Our study included 129 Japanese women with invasive, HER2-positive BC who received 12 cycles of paclitaxel or 4 cycles of docetaxel followed by 4 cycles of FEC-75 with concomitant trastuzumab for 24 weeks. We analyzed the correlation of pCR (no invasive lesions in the breast) and nodal status after NAC with RFS and OS, and analyzed the baseline expressions of ER, Ki-67, and p27 Kip1 , and histological grade for correlation with pCR. Positive or high expression was defined by nuclear labeling index: ER ≥10%, p27 Kip1 ≥75%, Ki-67 ≥30%. Results: In 129 patients, pCR was found in 85 (66%). Patients with pCR after NAC had significantly better RFS than those without pCR (median follow-up: 41 months). Furthermore, patients with pathologically negative nodes after NAC had significantly better OS than those with pathologically positive nodes. Negative ER (79% vs. 40%), high Ki-67 (72% vs. 47%), low p27 Kip1 (71% vs. 50%), and histological grade 3 (70% vs. 39%) were significant predictors of pCR. Conclusions: In patients with HER2-positive BC, this regimen was effective achieving the high pCR rate. pCR and pathologically negative nodes after NAC were predictive of RFS and OS, respectively. The expressions of ER, Ki-67, and p27 Kip1 , and histological grade at baseline were predictive of pCR. p27 Kip1 , a new predictor of pCR after NAC needs to be further analyzed.